Citations

Clear

3042 citation(s) found for "Kumar, S".

Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Krishna, R. Vijay , Giacomi, Federica De , Kalina, Peter , Baqir, Misbah , Krishna, Rachana, Krishna, Rachana, Kumar, Neeraj , Specks, Ulrich

Mayo Clinic

JCR: Journal of Clinical Rheumatology | September 17, 2019 | Volume: 27 | Issue: 2 | Pages: 64-72

10.1097/rhu.0000000000001169 | PMID 31567753 Get It

Objective To compare the effectiveness of rituximab (RTX) with cyclophosphamide (CYC) in patients who have central nervous system (CNS) involvement in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). Methods A computer-assisted search was conducted to identify all adults who received a diagnosis of AAV with CNS involvement from January 1, 1997, through July 1, 2017, at our institution. Results Of the 17 patients identified, 11 had received RTX, and 6 had received CYC. Age at diagnosis of CNS involvement was similar in both groups. In the RTX group, 91% of the patients were women; in the CYC group, 33% were women (p = 0.03). At the time of CNS presentation, orbital involvement had occurred in 6 patients in the RTX group and in none of the patients in the CYC group. Initial remission of induction was achieved in all patients (100%) in the CYC group and in 10 patients (91%) in the RTX group. Two patients had no response to RTX: 1 patient when RTX was used for remission induction at the time of diagnosis and the second patient when RTX was used for remission induction after relapse. The median follow-up was 38 months (range, 9–127 months). Central nervous system relapse occurred in 4 patients in the RTX group and in 1 patient in the CYC group. Of the 4 patients in the RTX group with relapse, 3 had marked ocular involvement. Both nonresponder patients in the RTX group had ocular involvement. Conclusion Rituximab is as effective as CYC in remission induction in patients with CNS involvement in AAV.
Accuracy of Accelerometers for Measuring Physical Activity and Levels of Sedentary Behavior in Children: A Systematic Review
Lynch, Brian , Kaufman, Tara K. , Rajjo, Tamim , Mohammed, Khaled , Kumar, Seema, Murad, M. Hassan , Gentile, Natalie, Koepp, Gabriel A., McCrady-Spitzer, Shelly , Levine, James A. , Lynch, Brian A , Rajjo, Tamim I, Gentile, Natalie E, Murad, M Hassan

Mayo Clinic

Journal of Primary Care & Community Health | September 11, 2019 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/2150132719874252 | PMID 31509061 Get It

Objectives: This systematic review evaluated the accuracy of triaxial and omnidirectional accelerometers for measuring physical activity and sedentary behavior in children. Design: Systematic review of the literature. Methods: We comprehensively searched several databases for studies published from January 1996 through June 2018 that reported diagnostic accuracy measures in children and adolescents (age 3-18 years) and compared accelerometers with energy expenditure using indirect calorimetry. Results: We included 11 studies that enrolled 570 participants. All studies used indirect calorimetry as the reference standard. Across the studies, median sensitivity ranged from 46% to 96% and median specificity ranged from 71% to 96%. Median area under the curve ranged from 69% to 98%. Conclusions: Accuracy measures were greatest when detecting sedentary behavior and lowest when detecting light physical activity. Accuracy was higher when the accelerometer was placed on the hip compared with the wrist. The current evidence suggests that triaxial and omnidirectional accelerometers are accurate in measuring sedentary behavior and physical activity levels in children.
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
Crow, Lauren , Jambusaria‐Pahlajani, Anokhi , Chung, Christina Lee , Baran, David A. , Lowenstein, Stefan E. , Abdelmalek, Mark, Ahmed, Rehana L. , Anadkat, Milan J. , Arcasoy, Selim M. , Berg, Daniel , Bibee, Kristin , Billingsley, Elizabeth M. , Black, William H., Blalock, Travis W. , Bleicher, Melissa, Brennan, Daniel C. , Brodland, David G., Brown, Mariah , Carroll, Bryan T. , Carucci, John A. , Chang, Timothy W., Chaux, George, Cusack, Carrie Ann, Dilling, Daniel F. , Doyle, Alden , Emtiazjoo, Amir , Ferguson, Nkanyezi H., Fosko, Scott W. , Fox, Matthew C., Göral, Simin , Gray, Alice , Griffin, John R., Hall, Shelley , Hanlon, Allison , Hayes, Don , Hickey, Gavin , Holtz, Jonathan E., Hopkins, R. Samuel, Hu, Jenny, Huang, Conway C. , Kapnadak, Siddhartha G. , Kraus, Edward S., Leitenberger, Justin J. , Lim, Mary Ann , Longo, María Isabel , Malik, Shahid M. , Menter, Alan , Myers, Sarah A., Neuburg, Marcy, Nijhawan, Rajiv I. , Norman, Douglas J., Otley, Clark C. , Paek, So Yeon , Parulekar, Amit , Patel, Manisha J., Patton, Timothy , Pugliano‐Mauro, Melissa , Ranganna, Karthik, Redenius, Rachel, Samie, Faramarz H. , Shin, Thuzar M. , Singer, Jonathan P. , Singh, Pooja , Soon, Seaver L. , Squires, Ronald A., Stasko, Thomas, Stein, Jennifer , Taler, Sandra J. , Thomas, Christie P. , Tokman, Sofya , Tomic, Rade , Twigg, Amanda R. , Wigger, M., Zeitouni, Nathalie C., Crow, Lauren D , Leca, Nicolae , Mallea, Jorge M. , Tomic, Rade , Singer, Jonathan P , Baran, David A , Paek, So Yeon , Ferguson, Nkanyezi , Hachem, Ramsey R. , Jiang, Shang I. Brian , Lease, Erika D. , Lee, James , Patel, Vishal Anil , Ravichandran, Ashwin Kumar , Redenius, Rachel A., Roll, Garrett Richard , Soriano, Teresa T. , Terrault, Norah A. , Arron, Sarah T. , Thomas, Christie P

Mayo Clinic

Transplant International | September 10, 2019 | Volume: 32 | Issue: 12 | Pages: 1268-1276

10.1111/tri.13520 | PMID 31502728 Get It

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes
Abeykoon, Jithma P. , Zanwar, Saurabh , Ansell, Stephen M. , Kumar, Shaji , Novak, Anne J. , King, Rebecca L. , Greipp, Patricia T. , Inwards, David J. , Muchtar, Eli , Thompson, Carrie A. , Dingli, David , Lacy, Martha Q. , Warsame, Rahma , Kyle, Robert A. , Kapoor, Prashant , Kumar, Shaji K , Greipp, Patricia, Inwards, David, Muchtar, E , Gonsalves, Wilson , Rajkumar, Vincent, Parikh, Sameer A , Dingli, David , Greipp, Patricia T , Gertz, Morie A. , Manske, Michelle K. , Go, Ronald S. , Habermann, Thomas M. , Witzig, Thomas E. , Leung, Nelson , Dispenzieri, Angela , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Parikh, Sameer A.

Mayo Clinic

British Journal of Haematology | August 30, 2019 | Volume: 188 | Issue: 3 | Pages: 394-403

10.1111/bjh.16168 | PMID 31468508 Get It

SummaryIbrutinib‐related data in Waldenström macroglobulinaemia (WM) remain sparse, particularly outside of trials. We report on 80 patients [previously treated, n = 67 (84%), treatment‐naïve, n = 13 (16%)] with WM, evaluated consecutively at Mayo Clinic, who received ibrutinib off‐study after its approval in 2015 for WM. Overall response rate (ORR) was 91%; major‐response rate (MRR) was 78%. The median time to first response and best response was 2·9 [95% confidence interval (CI): 2–4] and 5·7 (95% CI: 4–12) months, respectively. The median follow‐up was 19 (95% CI: 14–21) months; 18‐month progression‐free survival (PFS) was 82%. The median time on therapy was 12·5 (95% CI: 9·3–16·7) months, and the median duration‐of‐response was 32 (range: 23–32) months. Twenty‐five patients (31%) had discontinued therapy at last follow‐up (68% due to treatment‐related toxicities) and 18% of patients required dose reduction. Fatigue (12%) and atrial‐fibrillation (11%) were common non‐haematological toxicities. IgM rebound occurred in 36% of patients who abruptly discontinued ibrutinib. Following ibrutinib discontinuation, 84% of patients received subsequent treatment, achieving an ORR of 57% and MRR of 50%. The median PFS from commencement of subsequent salvage therapy was 18 months. Ibrutinib therapy, outside of clinical trials, is effective in WM, but is associated with toxicities and challenges, including IgM rebound and a high drug discontinuation rate for reasons other than disease progression.
Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B‐cell lymphomas in first remission in the rituximab era: A systematic review and meta‐analysis
Epperla, Narendranath , Hamadani, Mehdi , Reljic, Tea , Kharfan‐Dabaja, Mohamed A. , Savani, Bipin N. , Kumar, Ambuj , Savani, Bipin N , Hamadani, Mehdi , Epperla, Narendranath

Mayo Clinic

Cancer | August 23, 2019 | Volume: 125 | Issue: 24 | Pages: 4417-4425

10.1002/cncr.32464 | PMID 31441943 Get It

BackgroundThe outcomes for patients with diffuse large B‐cell lymphoma (DLBCL) with adverse clinical prognostic factors such as a high age‐adjusted International Prognostic Index (aaIPI) are not optimal. In the current study, the authors performed a systematic review and meta‐analysis to assess the totality of evidence pertaining to the efficacy of autologous hematopoietic stem cell transplantation (auto‐HCT) consolidation for patients with DLBCL in first remission.MethodsThe authors searched the Cochrane and MEDLINE/PubMed databases through December 1, 2018, for studies comparing conventional chemotherapy with rituximab (R‐chemo) versus R‐chemo and auto‐HCT. Two authors independently reviewed all references for study inclusion and extracted data related to benefits (overall survival, progression‐free survival, and response rates) and harms (treatment‐related mortality and adverse events).ResultsFour studies (1173 patients) met the inclusion criteria and were included in the current analysis. The median duration of follow‐up ranged from 42 to 76 months. There was no difference noted with regard to the overall survival (hazard ratio, 1.01; 95% CI, 0.74‐1.37), progression‐free survival (hazard ratio, 0.77; 95% CI, 0.58‐1.04), or response rates (risk ratio, 0.98; 95% CI, 0.92‐1.04) between patients who received R‐chemo and auto‐HCT and those who received R‐chemo alone. The risk of mortality and therapy failure was not found to be different when the analysis was limited to high aaIPI between the 2 groups. Although there was no difference noted with regard to the risk of treatment‐related mortality, there was a significantly higher incidence of CTCAE grade 3 or 4 adverse events in patients who received R‐chemo and auto‐HCT compared with patients treated with R‐chemo alone.ConclusionsThe findings from what to the authors' knowledge is the first meta‐analysis performed in the rituximab era demonstrated no beneficial effect of upfront auto‐HCT consolidation in patients with aggressive B‐cell non‐Hodgkin lymphoma, including high‐risk clinical groups (high aaIPI).
Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America
Goel, Ruchika , Gribbons, Katherine, Carette, Simon , Cuthbertson, David , Hoffman, Gary S., Koening, Curry L. , Kumar, Sathish , Langford, Carol A. , Maksimowicz‐McKinnon, Kathleen , McAlear, Carol A. , Moreland, Larry W. , Nair, Aswin , Quinn, Kaitlin A. , Ravindran, Raheesh, Sreih, Antoine G. , Warrington, Kenneth J. , Ytterberg, Steven R. , Grayson, Peter C. , Moreland, Larry W , Warrington, Kenneth J , Quinn, Kaitlin A , Joseph, George , Khalidi, Nader , Monach, Paul A. , Pagnoux, Christian , Seo, Philip , Merkel, Peter A. , Danda, Debashish

Mayo Clinic

Rheumatology | August 20, 2019 | Volume: 59 | Issue: 5 | Pages: 1118-1127

10.1093/rheumatology/kez421 | PMID 31580452 Get It

Abstract Objectives To develop and replicate, using data-driven methods, a novel classification system in Takayasu’s arteritis based on distribution of arterial lesions. Methods Patients were included from four international cohorts at major academic centres: India (Christian Medical College Vellore); North America (National Institutes of Health, Vasculitis Clinical Research Consortium and Cleveland Clinic Foundation). All patients underwent whole-body angiography of the aorta and branch vessels, with categorization of arterial damage (stenosis, occlusion or aneurysm) in 13 territories. K-means cluster analysis was performed to identify subgroups of patients based on pattern of angiographic involvement. Cluster groups were identified in the Indian cohort and independently replicated in the North American cohorts. Results A total of 806 patients with Takayasu’s arteritis from India (n = 581) and North America (n = 225) were included. Three distinct clusters defined by arterial damage were identified in the Indian cohort and replicated in each of the North American cohorts. Patients in cluster one had significantly more disease in the abdominal aorta, renal and mesenteric arteries (P < 0.01). Patients in cluster two had significantly more bilateral disease in the carotid and subclavian arteries (P < 0.01). Compared with clusters one and two, patients in cluster three had asymmetric disease with fewer involved territories (P < 0.01). Demographics, clinical symptoms and clinical outcomes differed by cluster. Conclusion This large study in Takayasu’s arteritis identified and replicated three novel subsets of patients based on patterns of arterial damage. Angiographic-based disease classification requires validation by demonstrating potential aetiological or prognostic implications.
Assessing Anticoagulation Management and Shared Decision-Making Documentation from Providers Participating in the SUPPORT-AF Study
Hoque, Laboni, Amroze, Azraa , Gilvaz, Vinit, Mazor, Kathleen M. , McManus, David D. , Kapoor, Alok , Abraham, Sonu , Lal, Amos , Mishra, Ajay Kumar , Crawford, Sybil L.

Mayo Clinic

No container title available | August 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.13133/v1 Get It

Abstract Background We previously tested an intervention featuring educational outreach with modified academic detailing (AD) to increase anticoagulation (AC) use in patients with atrial fibrillation (AF). Currently, we compare providers receiving and not receiving AD in terms of inclusion of our AD educational topics and shared decision-making elements in documentation. Methods Physicians reviewed themes discussed with providers during AD and evaluated charts for evidence of shared decision-making. We then compared frequency of documentation of individual items for providers receiving AD compared with non-AD providers. To understand baseline documentation practices of AD providers, we also randomly selected encounters of AD providers before their AD participation. Results There were 113 eligible encounters in the four months after AD - 36 from AD providers and 77 from non-AD providers. We also identified 35 encounters from AD providers before participating in the intervention. Providers infrequently documented many reviewed items (% documenting): AC mentioned (44%), multiple options for AC (5%), CHA2DS2-VASc score (11%), bleeding risk factors (2%). Compared with non-AD providers, AD providers had statistically significant higher percentages for the following items: mention of AC (64% versus 35%), stroke risk (11% versus 0%), AC benefits (8% versus 0%), patient involvement (70% versus 0%). There was no improvement, however, for AD providers compared with baseline documentation percentages. Conclusions Providers infrequently documented important items in AC management and shared decision-making. AD participation did not improve documentation. Improving adoption of AD educational items may require more prolonged interaction with providers. Improving shared decision-making may require an intervention more focused on it and its documentation. Trial Registration The trial was registered as NCT03583008 on Clinicaltrials.gov on July 11, 2018.
Time Horizons in Cost Analyses
Májer, István , Kumar, Shaji , Palmer, Stephen

Mayo Clinic

JAMA | August 13, 2019 | Volume: 322 | Issue: 6 | Pages: 582

10.1001/jama.2019.7853 | PMID 31408128 Get It

Clostridium difficile Infection in the Emergency Department
Garg, Sushil Kumar , Obaitan, Itegbemie , Sarvepalli, Shashank , Anugwom, Chimaobi M. , Pardi, Darrell S. , Khanna, Sahil , Garg, Sushil K

Mayo Clinic

Journal of Clinical Gastroenterology | August 12, 2019 | Volume: 54 | Issue: 4 | Pages: 350-355

10.1097/mcg.0000000000001252 | PMID 31403981 Get It

Introduction: Clostridioides difficile infection (CDI) is associated with substantial emergency department (ED) and inpatient burden. To date, few studies have evaluated the ED burden of CDI. Using the Nationwide Emergency Department Sample, we evaluated trends in ED use, ED and inpatient charges, admission and mortality rates, length of stay, and independent risk factors for hospital admission and mortality after an ED visit. Methods: Using Nationwide Emergency Department Sample for 2006 through 2014, we identified all patients with the primary diagnosis of CDI (using diagnostic codes). We determined the trends in ED visits and used survey logistic regression analysis to identify factors associated with hospital admission. Results: Overall, 909,236 ED visits for CDI resulted in 817,935 admissions (90%) to the hospital. The number of visits increased from 76,709 in 2006 to 106,869 in 2014, and the admission rate decreased from 92.4% to 84.4%. ED charges adjusted for inflation went up from US$1433.0 to 2900, a significant rise even accounting for inflation. The overall length of hospital stay decreased from 7 to 5.8 days. Independent predictors of admission after ED visits included smoking, use of alcohol, and presence of multiple comorbidities. Independent risk factors for mortality in admitted patients include increasing age and presence of comorbidities. Conclusions: Although ED use for CDI increased, rates of hospital admission decreased over 9 years. Identification of predictors of admission and in-hospital mortality will help guide policies and interventions to reduce the burden on health care resources.
Why are we performing fewer cholecystectomies for mild acute biliary pancreatitis? Trends and predictors of cholecystectomy from the National Readmissions Database (2010–2014)
Garg, Sushil Kumar , Bazerbachi, Fateh , Sarvepalli, Shashank , Majumder, Shounak , Vege, Shanthi Swaroop, Bazerbachi, F , Majumder, Shounak

Mayo Clinic

Gastroenterology Report | August 8, 2019 | Volume: 7 | Issue: 5 | Pages: 331-337

10.1093/gastro/goz037 | PMID 31687152 Get It

Abstract Background Current guidelines recommend cholecystectomy for patients with mild acute biliary pancreatitis (MABP) during the index admission because it is associated with better outcomes. In this study, we aimed to assess national trends in cholecystectomy during index admissions for MABP and to identify factors associated with cholecystectomy completion and 30-day readmission. Methods Using diagnostic codes and the National Readmissions Database, we identified patients admitted with MABP between 2010 and 2014. Differences in cholecystectomy rates were computed on the basis of various characteristics. We conducted a multivariable analysis to identify factors associated with 30-day readmission and cholecystectomy during the same admission. Results We identified 255,695 unique index MABP cases (41.3% male) and the 30-day readmission rate was 12.6%. Overall, 43.8% underwent cholecystectomy and 25% underwent endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy. We observed a decreasing trend in both procedures during the study period (P < 0.001). In multivariate analysis, odds of 30-day readmission were reduced for patients undergoing ERCP with sphincterotomy (odds ratio, 0.78; 95% confidence interval, 0.74–0.84) or cholecystectomy (odds ratio, 0.37; 95% confidence interval, 0.35–0.39). Conclusions For patients with MABP, cholecystectomy or ERCP with sphincterotomy during the index admission decreased the risk of 30-day readmission. Despite this benefit and national guidelines recommending cholecystectomy during the index MABP admission, the rate of cholecystectomies performed nationally decreased during the study period. Further research is needed to understand the implications and reasons underlying this deviation from guidelines.